Melanoma: An immunotherapy journey from bench to bedside

Vishal Navani(Hunter Medical Research Institute), Nikola A. Bowden(Hunter Medical Research Institute), Martin Hong(Calvary Mater Newcastle Hospital), Jennifer Martin(Ministry of Children, Community and Social Services), André van der Westhuizen(Hunter Medical Research Institute), Moira C. Graves(Hunter Medical Research Institute), Hiren Mandaliya(Lake Macquarie Private Hospital)
Cancer treatment and research
January 1, 2022
10.1007/978-3-030-96376-7_2
Cited by 2

Related Papers

Reducing Inappropriate Polypharmacy
|JAMA Internal Medicine|2015|1.5k
BCL-2 family isoforms in apoptosis and cancer
|Cell Death and Disease|2019|706
Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI)
|Translational Lung Cancer Research|2019|392
Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study
|Gastroenterology|2016|226
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
|Journal of Clinical Oncology|2022|166